What are my options availableafter failing recurrent mesonephric-like adenocarcinoma (MLA) of the ovary

Ovarian CancerNovember 5, 2025Navis AIExpert Reviewed

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

or Upload your records for answers about your actual case

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Reviewed by Dr. Chris Apfel, MD/PhD (UCSF)

Treatment Options for Recurrent Mesonephric-Like Adenocarcinoma of the Ovary

I appreciate you sharing this specific diagnosis. I want to be direct with you: mesonephric-like adenocarcinoma (MLA) of the ovary is a rare tumor type, and I need to be honest about the limitations of what I can tell you based on standard guidelines.

What I Found in Major Guidelines

After reviewing current guidelines from the NCCN (National Comprehensive Cancer Network) and American Cancer Society, I found that these organizations provide detailed recommendations for common ovarian cancers (like high-grade serous carcinoma and clear cell carcinoma), but MLA is not specifically addressed in their standard treatment algorithms because it's so uncommon.

This is actually important information for you to know—it means your care team needs to take a more individualized approach.

What You Should Do Now

I strongly recommend:

Consult with a gynecologic oncologist who specializes in rare ovarian tumors, ideally at a comprehensive cancer center
Ask your team about:
- Molecular testing (genetic analysis of your tumor) to identify specific mutations or biomarkers that might guide treatment
- Whether clinical trials might be appropriate for your situation
- Referral to a rare cancer specialist or tumor board review
Explore resources like:
- Cancer Commons (cancercommons.org) - specializes in rare and complex cancers
- National Cancer Institute (NCI) - can help connect you with specialists
- Clinical trial databases at clinicaltrials.gov

Why This Matters

Because MLA is rare, treatment decisions are often based on:

How your specific tumor behaves
What mutations it has
What worked (or didn't work) in your previous treatment
Similar tumor types' responses to therapy

Would you like help preparing questions for your oncology team, or information about how to access rare cancer specialists?

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

or Upload your records for answers about your actual case

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →